Vistagen therapeutics announces last patient completes dosing in the elevate phase 2 clinical study of av-101 for major depressive disorder

Vistagen therapeutics announced that the last patient has completed dosing in the elevate phase 2 clinical study of av-101, the company's novel, oral nmda (n-methyl-d-aspartate) receptor glycine site antagonist, as an adjunctive (add-on) treatment with an fda-approved oral antidepressant for major depressive disorder (mdd). the company remains on track to report top line results of the elevate study before the end of 2019. av-101 (4-cl-kyn) belongs to a new generation of investigational medicines in neuropsychiatry and neurology known as nmda glutamate receptor modulators. the nmda receptor is a pivotal receptor in the brain and abnormal nmda function is associated with numerous cns diseases and disorders. av-101 is an oral prodrug of 7-cl-kyna, a potent and selective full antagonist of the glycine coagonist site of the nmda receptor. with its exceptional safety profile in all studies to date, av-101 has potential to be a new at-home treatment for multiple large market cns indications where current treatments are inadequate to satisfy high unmet patient needs. vistagen is currently focused on av-101's potential to treat depression, dyskinesia associated with levodopa therapy for parkinson's disease, epilepsy, neuropathic pain and suicidal ideation.
VTGN Ratings Summary
VTGN Quant Ranking